Bioxodes, a Gosselies, Belgium-based clinical stage biopharmaceutical company, raised €2.7M in Series A extension funding.
Backers were not disclosed.
Led by CEO Marc Dechamps, Bioxodes is a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, it has developed its lead asset BIOX-101, a drug candidate aimed at patients with thrombo-inflammatory disease. Its mechanism of action is the foundation of an innovative pipeline of drug candidates for the prevention of (thrombo-)inflammatory diseases.
The company intends to use the funds to deliver full results from BIRCH, its Phase 2a trial of BIOX-101 to treat intracerebral hemorrhage (ICH), an orphan disease with no currently approved therapeutic intervention, and prepare for the launch of a potentially registrational Phase 2b trial of BIOX-101 for ICH.
FinSMEs
12/02/2025